Abstract
We studied the effect of the 5-HT1A receptor antagonist, pindolol, on the prolactin (PRL) response to the 5-HT releasing agent,d-fenfluramine (d-FEN), in ten healthy male volunteers. Pindolol pretreatment lowered baseline PRL levels but, when this effect was taken into account, did not significantly attenuate the PRL response tod-FEN. Within the limitations that attend the use of pindolol as a 5-HT1A receptor antagonist, the data suggest that although 5-HT1A receptors may play a role in the tonic release of PRL, they are not involved in the release of PRL produced byd-FEN. We propose that the PRL response tod-FEN may involve selective activation of postsynaptic 5-HT2 receptors.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Barone P, Jordan D, Atger F, Kopp N, Fillion G (1994) Quantitative autoradiography of 5-HT1D and 5-HT1E binding sites labelled by [3H]5-HT, in frontal cortex and the hippocampal region of the human brain. Brain Res 638:85–94
Blue ME, Yagaloff KA, Mamounas LA, Hartig PR, Molliver ME (1988) Correspondence between 5HT2 receptors and serotonergic axons in rat neocortex. Brain Res 453:315–328
Cowen PJ, Anderson IM, Grahame-Smith DG (1990) Neuroendocrine effects of azapirones. J Clin Psychopharmacol 10:21S-25S
Di Renzo G, Amoroso S, Taglialatela M, Canzoniero L, Basile V, Fatatis A, Annunziato L (1989) Pharmacological characterization of serotonin receptors involved in the control of prolactin secretion. Eur J Pharmacol 162:371–373
Fuller R (1992) The involvement of serotonin in regulation of pituitary-adrenocortical function. Front Neuroendocrinol 13:250–270
Gartside SE, Cowen PJ (1990) Mediation of ACTH and prolactin responses to 5-HTP by 5-HT2 receptors. Eur J Pharmacol 179:103–109
Gilbert F, Brazell C, Tricklebank MD, Stahl SM (1988) Activation of the 5-HT1A receptor subtype increases rat plasma ACTH secretion. Eur J Pharmacol 147:431–439
Goodall EM, Cowen PJ, Franklin M, Silverstone T (1993) Ritanserin attenuates anorectic, endocrine and thermic responses tod-fenfluramine in human volunteers. Psychopharmacology 112:461–466
Haleem DJ, Kennet GA, Whilton PS, Curzon G (1989) 8-OH-DPAT increases corticosterone but not other 5-HT1A receptor-dependant responses more in females. Eur J Pharmacol 164:435–443
Hjorth S, Carlsson A (1986) Is pindolol a mixed agonist-antagonist at central serotonin (5-HT) receptors? Eur J Pharmacol 129:131–138
Hoyer D (1988) Funcional correlates of serotonin 5-HT1 recognition sites. J Recept Res 8:59–81
Kahn RS, Wetzler S, Asnis GM, Kling MA, Suckow RF, Van Praag HM (1990) Effects ofm-chlorophenylpiperazine in normal subjects: a dose-response study. Psychopharmacology 100:339–344
Koenig JL, Gudelsky GA, Meltzer HY (1987) Stimulation of corticosterone andβ-endorphin secretion in the rat by selective 5-HT receptor subtype activation. Eur J Pharmacol 137:1–8
Laakmann G, Hinz A, Voderholzer U, Daffner C, Muller OA, Neuhauser H, Neulinger E, Wittman M (1990) The influence of psychotropic drugs and releasing hormones on anterior pituitary hormone secretion in healthy subjects and depressed patients. Pharmacopsychiatry 23:18–26
Meltzer HY, Maes M (1994) Effect of pindolol on thel-5-HTP-induced increase in plasma prolactin and cortisol concentrations in man. Psychopharmacology 114:635–643
Molliver ME (1987) Serotonergic neuronal systems: what their anatomic organization tells us about function. J Clin Psychopharmacol 7:3S-23S
Mueller EA, Murphy DL, Sunderland T, Jones J (1985) A new post-synaptic serotonin agonist suitable for studies in humans. Psychopharmacol Bull 21:701–704
Oksenberg D, Marsters SA, O'Dowd BF, Jin H, Havlik S, Peroutka SJ, Ashkenazi A (1992) A single amino-acid difference confers major pharmacological variation between human and rodent 5-HT1B receptors. Nature 360:161–163
Power A C, Cowen P J (1992) Neuroendocrine challenge tests: assessment of 5-HT function in anxiety and depression. Mol Aspects Med 13:205–220
Richards RP, Gordon BH, Ings RMJ, Campbell DB, King LJ (1989) The measurement ofd-fenfluramine and its metabolite,d-norfenfluramine in plasma and urine with an application of the method to pharmacokinetic studies. Xenobiotica 19:547–553
Schwartz D, Hernandez L, Hoebel BG (1989) Fenfluramine administered systemically or locally increases extracellular serotonin in the lateral hypothalamus as measured by microdialysis. Brain Res 482:261–270
Series HG, Cowen PJ, Sharp T (1994)p-Chloroamphetamine (PCA), 3,4-methylenedioxymethamphetamine (MDMA) andd-fenfluramine pretreatment attenuates d-fenfluramine-evoked release of 5-HT in vivo. Psychopharmacology (in press)
Smith CE, Ware CJ, Cowen PJ (1991) Pindolol decreases prolactin and growth hormone responses to intravenousl-tryptophan. Psychopharmacology 103:140–142
Tricklebank MD, Forler C, Fozard JR (1984) The involvement of subtypes of the 5-HT1 receptor and of catecholaminergic systems in the behavioural response to 8-hydroxy-2-(di-n-propylamino) tetralin. Eur J Pharmacol 106:271–282
Van de Kar LD, Urban JH, Richardson KD, Bethea CL (1985) Pharmacological studies on the serotoninergic and nonserotonin-mediated stimulation of prolactin and corticosterone secretion by fenfluramine. Neuroendocrinology 41:283–288
Yatham LN, Steiner M (1993) Neuroendocrine probes of serotonergic function: a critical review. Life Sci 53:447–463
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Park, S.B.G., Cowen, P.J. Effect of pindolol on the prolactin response tod-denfluramine. Psychopharmacology 118, 471–474 (1995). https://doi.org/10.1007/BF02245948
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF02245948